Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
Genentech Drug Offers Oral, at-Home Option for SMA Patients
Enabling Precision Medicine through Proteomics
Battling Drug-Resistant Fungal Infections
Making Colorectal Cancer Screening Less of a Pain in the Ass
Targeting Diseases of Aging at a Cellular Level
Cracking the Immune System with AI
Using AI to Improve Drug Companies’ Regulatory Performance
Delivering Biologics Orally
Turning Proteins into Device Coatings that Provide Therapeutic Benefits
Testing if an Approved Antiviral May Prevent COVID-19 Outbreaks
Using AI to Crack COVID-19
Why An Experimental Therapy for Inflammatory Disorders Could Help the Fight Against COVID-19
Modernizing Phage Therapy to Kill Multidrug-Resistant Bacteria
A Rare Disease Drug Hunter Turns His Attention to COVID-19
What It Will Take to Move Beyond the Pandemic
Reading, Writing, and Erasing the Way to Epigenetic Cancer Therapies
Better Immunotherapies Through Chemistry
Bringing the Trial to the Patient
Controlling the Activity of Cell and Gene Therapies with Precision
Why Soon-Shiong Thinks His Triangle Offense for Cancer Can Be Applied to COVID-19
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths